WT
FSTX

Washington Trust’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Washington Trust’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-233
Closed -$11K – 881
2018
Q2 		$11K Buy
+233
New +$12.9K ﹤0.01% 667

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

Washington Trust's FSTX Position: Q3 2018 in Review

Washington Trust sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2018, closing a stake of 233 shares — an estimated $11K sold.

Washington Trust first reported a position in FSTX in Q2 2018 and held it in 1 quarter. The position peaked at $11K in Q2 2018. 51 funds tracked by Wall St. Rank hold FSTX as of Q3 2018.

  • Washington Trust reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Washington Trust sold 233 F-star Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $11K.
  • Washington Trust first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Washington Trust's F-star Therapeutics, Inc. Common Stock position peaked at $11K in Q2 2018.
  • 51 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Washington Trust's 13F filing for Q3 2018, filed 13 Nov 2018.